Efficacy of Methimazole Dosing Algorithm

Efficacy of Methimazole Dosing Algorithm

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT05964452

Recruitment Status : **RECRUITING NOW**
First Posted : July 28, 2023
Last Update Posted : July 28, 2023

Sponsor:

Information provided by (Responsible Party):
Dan Mihailescu, Cook County Health

Go to 

Brief Summary:
To prospectively study the efficacy and safety of the Cook County Health (CCH) methimazole (MMI) dosing algorithm in the setting of new onset Graves’ disease.

Graves Disease
Drug: Methimazole Tablets

Detailed Description:
We aim to conduct a prospective observational study in 60 patients with newly diagnosed Graves’ disease who are either methimazole naive or who have been initiated on MMI within previous 4-6 weeks per CCH algorithm. The patient number is based on 90% power and projected efficacy of 70% patients reaching target.

Go to 

Layout table for study information

Study Type :
Observational

Estimated Enrollment :
60 participants

Observational Model:
Case-Only

Time Perspective:
Prospective

Official Title:
The Efficacy of Cook County Health’s Methimazole Dosing Algorithm in the Setting of ne Onset Graves’ Hyperthyroidism

Actual Study Start Date :
February 14, 2022

Estimated Primary Completion Date :
February 14, 2024

Estimated Study Completion Date :
February 14, 2024

Resource links provided by the National Library of Medicine

Go to 

Intervention Details:

Go to 

Primary Outcome Measures :

Achievement of euthyroid state [ Time Frame: 17 weeks ]
The proportion of patients achieving euthyroid state during the study period

Secondary Outcome Measures :

Factors influencing achievement of euthyroid state [ Time Frame: 17 weeks ]
Identifying variables that correlate with achievement of euthyroid state

Go to 

Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:  
18 Years and older   (Adult, Older Adult)

Sexes Eligible for Study:  
All

Accepts Healthy Volunteers:  
No

Sampling Method:  
Non-Probability Sample

Adults with new onset Graves’ disease.

Inclusion Criteria:

Non-pregnant adults (>18 years of age) with new diagnosis of Graves’ Disease (elevated free T4, Free T3, low or suppressed TSH, positive TSI and or thyroid eye disease) and
either drug naïve or who have been initiated on MMI within previous 4-6 weeks per CCH algorithm.

Exclusion Criteria:

Pregnant patients
hyperthyroidism due to other causes, example – Toxic Multinodular Goiter, Iodine induced thyrotoxicosis, etc.
Graves patients who present with atrial fibrillation, CHF or other end organ damage

Go to 

Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05964452

Layout table for location information

Cook County Health

Chicago, Illinois, United States, 60612

Contact: Dan Mihailescu, MD    312-864-0531    dan.mihailescu@cookcountyhhs.org   

Cook County Health

Layout table for investigator information

Principal Investigator:
Dan Mihailescu, MD
Cook County Health

Go to 

Layout table for additonal information

Responsible Party:
Dan Mihailescu, MD Endocrinology Cluster Director, Cook County Health

ClinicalTrials.gov Identifier:
NCT05964452    

Other Study ID Numbers:
22-010

First Posted:
July 28, 2023    Key Record Dates

Last Update Posted:
July 28, 2023

Last Verified:
July 2023

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:
No

Studies a U.S. FDA-regulated Device Product:
No

Additional relevant MeSH terms:

Layout table for MeSH terms

Graves DiseaseExophthalmosOrbital DiseasesEye DiseasesGoiterThyroid DiseasesEndocrine System DiseasesHyperthyroidism
Autoimmune DiseasesImmune System DiseasesMethimazoleAntithyroid AgentsHormone AntagonistsHormones, Hormone Substitutes, and Hormone AntagonistsPhysiological Effects of Drugs

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 1, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments